Anondita Medicare Ltd H1 FY26 – ₹54 Cr Half-Year Sales, 35% OPM, ₹7.11 EPS & a ₹1,300 Cr Market Cap Riding on Condoms and Courage
1. At a Glance – Latex, Leverage, and Loud Valuations
Anondita Medicare Limited is one of those companies that makes you pause your scrolling, raise an eyebrow, and quietly whisper, “Wait… condoms?” Founded in March 2024, listed in September 2025, and already commanding a market capitalisation of around ₹1,302 crore at a stock price of ₹720, this Noida-based manufacturer of flavoured male condoms under the unapologetically bold “COBRA” brand has sprinted onto Dalal Street like it skipped foreplay. In just its first reported half-year (H1 FY26), the company clocked ₹54 crore in sales, ₹19 crore in operating profit, and a net profit of ₹13 crore, translating into a muscular operating margin of 35% and an EPS of ₹7.11 for the half-year. The stock has doubled in three months, the P/E is hovering around 56–57x, and the price-to-book is a jaw-dropping 12x for a company whose book value is about ₹60 per share. Debt stands at ₹46.6 crore, promoter holding is a comfortable 61.8%, and dividend yield is a proud zero. This is not a sleepy FMCG play; this is a high-voltage SME story where government tenders, latex capacity, and IPO money are all colliding at once. Curious already? You should be.
2. Introduction – From Bedroom Product to Boardroom Darling
Condoms are not exactly dinner-table conversation in Indian households, but Anondita Medicare has dragged them straight into investor WhatsApp groups. The company entered the public markets barely a year after being founded, which itself is enough to make conservative investors clutch their mutual fund statements. Yet here we are, staring at half-year numbers that many five-year-old listed companies would envy. The flagship brand “COBRA” is not subtle, the margins are not shy, and the valuation is definitely not apologetic.
What makes this story fascinating is the speed. In FY24, the company was still transitioning out of COVID-era trading products like gloves and masks. By Q1 FY25, condoms already contributed 99.92% of revenue. By H1 FY26, the company is talking about UN qualification, export relaunches, female condoms, and scaling government orders. All this while sitting on an installed capacity of 56.2 crore pieces per annum, of which only about 39% was utilised in FY24. In other words, the factory is large, the machines are ready, and the balance sheet has just been freshly moisturised with IPO proceeds.
But before we get carried away and start treating this like a FMCG unicorn in latex clothing, it’s important to slow down, unzip the numbers carefully, and see what’s really going on under the hood. Is this a durable compounding story or just a well-lubricated one-time run driven by government tenders? Let’s find out.
3. Business Model – WTF Do They Even Do?
At its core, Anondita Medicare manufactures condoms. Male condoms primarily, flavoured ones to be precise, and recently female condoms as well, for which the company claims to have a manufacturing patent. The production process is fully in-house, including printing and packaging, and every condom goes through 100% electronic testing. So yes, quality control here is literally non-negotiable.
The manufacturing facility is located in Noida, Uttar Pradesh, spread across about 11,000 square feet. The installed capacity of 56.2 crore pieces per annum is substantial for a company of this age, but what’s more interesting is the underutilisation. At roughly 39% utilisation in FY24, the company has a lot of headroom to grow without immediately pouring more money into bricks and machines. This is where operating leverage comes into the bedroom—sorry, boardroom.
Revenue is driven largely by domestic sales, and within that, government procurement plays a starring role. Agencies like CMSS (Central Medical Services Society) and various AIDS Control Societies form a significant chunk of demand. On the private side, distributors like Calcutta Cosmetics and the company’s own subsidiary, Anondita Healthcare & Rubber Products (I) Ltd, push volumes through trade channels.
The business model is simple, scalable, and brutally volume-driven. You win tenders, you run machines, you ship boxes, and you book margins. There is no SaaS-style recurring revenue magic here, but there is predictability as long as government orders keep flowing. The big question is: can the brand “COBRA” eventually stand tall in retail shelves alongside names like Durex or Manforce, or will Anondita remain a tender-driven latex factory? What do you think?
4. Financials Overview – The Numbers Don’t Blush
Result Type Lock: The latest official heading clearly states Half Yearly Results. This is treated as HALF-YEARLY RESULTS and locked.
Half-Year Financial Comparison (₹ in Crores)
Source table
Metric
Latest Half (Sep 2025)
Same Half Last Year (Sep 2024)
Previous Half
YoY %
HoH %
Revenue
54
31
NA
74.2%
NA
EBITDA
19
10
NA
90.0%
NA
PAT
13
6
NA
116.7%
NA
EPS (₹)
7.11
4.29
NA
65.7%
NA
Now let’s annualise the EPS properly. Since this is half-yearly data:
Annualised EPS = ₹7.11 × 2 = ₹14.22
At a current price of ₹720, this implies a recalculated P/E of roughly 50.6x, slightly lower than the trailing number floating around, but still rich enough to make value investors sweat.
The standout here is margin expansion. Operating margins improved from 31% to 35% year-on-year, which is no joke in a manufacturing business. This tells us two things: one, pricing power exists in government and bulk contracts (surprising but true), and two, operating leverage is kicking in as volumes scale.
But remember, there is no previous half comparison yet because the company is basically a financial toddler. We are judging a sprint, not a marathon. Does this pace sustain? Or does it trip over inventory and receivables? Keep reading.
5. Valuation Discussion – Stretchy, Not Snapped (Yet)
Let’s talk valuation, and yes, let’s keep our clothes on.
1) P/E Method
Annualised EPS: ₹14.22 Assumed reasonable P/E range for niche FMCG/healthcare SME with high growth: 35x to 45x
If we assume a more sustainable EV/EBITDA range of 25x to 30x:
Lower EV: ₹38 × 25 = ₹950 crore
Upper EV: ₹38 × 30 = ₹1,140 crore
After adjusting for net debt, this again points to a valuation band below current levels.
3) DCF (Simplified, Educational)
Given limited history, any DCF here is more art than science. Assuming high growth in the near term, margin stability, and gradual normalisation, the implied
